RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer

RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer is organized by Global Oncology Academy (GOA).

Publication Dates
Release Date: 12/08/2023
Expiration Date: 12/08/2024

Description:
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients. 

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Critically evaluate components of RWE publications to distinguish high-quality from low-quality sources of information
• Evaluate RWE of CDK4/6 inhibitors in HR+/HER2- MBC as it relates to clinical trial evidence
• Apply RWE to make treatment decisions for patients regarding the choice of CDK4/6 inhibitors in HR+/HER2- MBC
• Increase clinician awareness of the patient's perspective on the existence and utility of RWE as it applies to shared decision-making conversations